Press Releases Year None2024202320222021202020192018 Mar 08, 2024 Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Mar 07, 2024 Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology Mar 05, 2024 Akero Therapeutics Announces Pricing of Public Offering of Common Stock Mar 04, 2024 Akero Therapeutics Announces Proposed Public Offering of Common Stock Mar 04, 2024 Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study Feb 29, 2024 Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH Feb 29, 2024 Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Jan 03, 2024 Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Year None2024202320222021202020192018 Mar 08, 2024 Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Mar 07, 2024 Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology Mar 05, 2024 Akero Therapeutics Announces Pricing of Public Offering of Common Stock Mar 04, 2024 Akero Therapeutics Announces Proposed Public Offering of Common Stock Mar 04, 2024 Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study Feb 29, 2024 Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH Feb 29, 2024 Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Jan 03, 2024 Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Mar 08, 2024 Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Mar 07, 2024 Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
Mar 04, 2024 Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
Feb 29, 2024 Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
Feb 29, 2024 Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update